WO2001047559A1 - Pastilles a usage externe - Google Patents
Pastilles a usage externe Download PDFInfo
- Publication number
- WO2001047559A1 WO2001047559A1 PCT/JP2000/007451 JP0007451W WO0147559A1 WO 2001047559 A1 WO2001047559 A1 WO 2001047559A1 JP 0007451 W JP0007451 W JP 0007451W WO 0147559 A1 WO0147559 A1 WO 0147559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- water
- external patch
- containing base
- analgesic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to an anti-inflammatory and analgesic external preparation. Specifically, a drug containing a sticky gel base containing water-soluble polymer substances, a cross-linking agent, water, and a water retention agent as essential components, and a local anesthetic and a non-steroid antiphlogistic analgesic as active ingredients
- the present invention relates to an external patch having a drug protective layer comprising a base and having markedly improved anti-inflammatory and analgesic effects.
- many non-steroid anti-inflammatory analgesics with excellent anti-inflammatory, analgesic, and antipyretic effects have been developed and are widely used for rheumatic diseases, pain after surgery or after thread removal.
- non-steroid anti-inflammatory analgesics were initially developed as oral preparations and are still used as useful therapeutic agents.However, when these non-steroid anti-inflammatory analgesics are administered orally, they cause gastrointestinal dysfunction. There may be side effects such as tract damage.
- the drug is administered for the purpose of selective drug distribution to the affected area and reduction of side effects such as gastrointestinal tract disorders when administered orally.
- route change is achieved, however c ointment or solution has been developed as an external preparation, these ointment or liquid preparation, the dosage and constant difficult to Rukoto the coating area, also applied site base rattling, Often, there are problems in use such as adhesion to clothing.
- patches are mentioned as preparations having the same effect as ointments or liquid preparations. Patches are applied to the skin and allow the drug to be absorbed transdermally into the body.Many of the advantages of ointments, such as accurate dosage, easy administration, and the effect of sealing the preparation in the affected area, etc. Therefore, its usefulness is expected because of its long-lasting effect by sustained absorption of the drug.
- Japanese Patent Application Laid-Open Nos. Hei 2-21-2324, Hei 4 828 28, Hei 8-319 243, Hei 9-124 As can be seen in Publication No.
- An object of the present invention is to provide an external patch which can improve an analgesic effect of pain accompanying inflammation such as rheumatoid arthritis, osteoarthritis, and low back pain.
- the present inventors have conducted intensive studies to solve the above problems, and as a result, have found that a water-soluble polymer material, a cross-linking agent, water and a water-retaining agent are essential components of an adhesive gel base, An external patch that is simultaneously coated with a steroid-based anti-inflammatory analgesic is coated on a support to provide an excellent drug release control function and to transdermally deliver the drug over a long period of time. It can be absorbed, and it is found that the anti-inflammatory effect and the local analgesic effect are extremely excellent in the analgesic effect of pain associated with inflammation such as rheumatoid arthritis, osteoarthritis, and low back pain, thereby completing the present invention. Reached.
- the present invention relates to an external patch comprising a support and a drug holding layer coated on the support, wherein the drug holding layer comprises a water-soluble polymer substance, a crosslinking agent, water, and water retention.
- An external patch characterized by comprising a drug-containing base consisting of a local anesthetic and a non-steroid anti-inflammatory analgesic as the active ingredients, in addition to an adhesive gel base containing an active ingredient as an essential component I do.
- the present invention provides the method of the present invention, wherein the local anesthetic is selected from the group consisting of tetracaine, proforce, jib forcein, lidocaine, benzocaine, xylocaine, and a pharmaceutically acceptable salt thereof.
- the above external patch is characterized by comprising two or more compounds.
- the present invention provides the method, wherein the non-steroid anti-inflammatory drug comprises indomethacin, ketope oral fen, piroxicam, fenorebinac, bufexamac, s: 7 ° oral fen, fuzore norrebiprofen, diclofenac, ibuprofen, and pharmaceutically acceptable salts thereof.
- the above external patch is characterized by comprising one or two or more compounds selected from the group consisting of salts described below.
- the present invention also provides any of the above external patches, wherein the local anesthetic is contained in the drug-containing base in an amount of 0.1 to 50% by weight.
- the present invention also provides any one of the above external patches, wherein the non-steroid anti-inflammatory drug is contained in the drug-containing base in an amount of 0.05 to 10% by weight. provide.
- the present invention will be described in detail.
- the external patch of the present invention has a support and a drug holding layer coated on the support,
- the support used for the external patch of the present invention is not particularly limited as long as it is one commonly used for patches in the art.
- Such supports include, for example, Polyester, polychlorinated vinyl, lint cloth, nylon, non-woven fabric or a composite material thereof.
- a liner of an appropriate material for example, polypropylene film, polyethylene film, polyurethane film, etc.
- the thickness of the support is not particularly limited, and can be appropriately determined depending on the use.
- the drug holding layer of the external patch of the present invention comprises a drug-containing base comprising a local anesthetic and a non-steroid antiphlogistic analgesic as a medicinal component in an adhesive gel base.
- a drug-containing base comprising a local anesthetic and a non-steroid antiphlogistic analgesic as a medicinal component in an adhesive gel base.
- the adhesive gel base used in the present invention contains a water-soluble polymer substance, a crosslinking agent, water and a water retention agent as essential components.
- water-soluble polymer substance examples include gelatin, starch, agar, mannan, alginic acid, polyacrylic acid, polyacrylate, dextrin, methylcellulose, hydroxypropinoresenolerose, methylcellulose sodium, and canoleboximethyme.
- examples include norecellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinyl pyrrolidone, methyl butyl ether monoanhydride maleic copolymer, arabia gum, tragacanth gum, karaya gum, locust bean gum and the like.
- These water-soluble polymer substances are mainly used to bring out the physical properties and desired physical properties of other raw materials used in the above-mentioned adhesive gel base: These may be used alone or in combination of two or more. Can be used.
- the amount of the water-soluble polymer substance in the adhesive gel base is 0.5 to 50% by weight. /. And more preferably 5 to 25% by weight. It is preferable that the content of the water-soluble polymer be in the above-mentioned range since the feeling of use such as water retention and adhesive strength is improved.
- any of an organic and inorganic crosslinking agent may be used, but an aluminum compound is preferably used.
- Aluminum compounds include aluminum hydroxide, aluminum chloride, hydrous aluminum silicate, and synthetic silicate. Lumidium, dried aluminum hydroxide gel, aluminum acetate, aluminum lactate, aluminum stearate, magnesium aluminate metasilicate, dihydroxyaluminum amino acetate, and the like.
- These cross-linking agents give the gel an appropriate strength as its initial physical properties, and prevent cross-linking with polymer substances efficiently to prevent a decrease in gel strength. It can improve the workability, the workability, and the usability.
- These crosslinking agents can be used alone or in combination of two or more.
- the amount of the crosslinking agent in the adhesive gel base is 0.0001 to 10 weight. /. And more preferably 0.01 to 5% by weight.
- purified water sterilized water, or ion-exchanged water is preferably used.
- the water improves the swelling of the stratum corneum and the permeability of the drug.
- the content of the water in the adhesive gel base is 10 to 80% by weight. / 0 is preferred, and more preferably in the range of 20 to 60% by weight.
- water-retaining agent in the present invention examples include polyhydric alcohols such as ethylene glycol, diethylene glycol, polyethylene glycol, glycerin, so / levitol, maltitol, propylene glycol, and 1,3-butylene glycol.
- Saccharides such as sodium hyaluronate, starch-acrylonitrile graft, starch-acrylic acid graft, starch-styrenesulfonic acid graft, starch-vinylsulfonic acid graft, polyvinyl alcohol crosslinked, Highly absorbent resins such as cross-linked polyethylene glycol diacrylate and acrylic acid-vinyl acetate saponified products.
- These water retention agents are used to maintain a constant amount of water in the adhesive gel base and to suppress the adverse effect on the drug release rate to the skin due to water evaporation during storage or use of the intended patch. Can be These can be used alone or in combination of two or more.
- the amount of the water retention agent in the adhesive gel base is preferably 0.01 to 80% by weight, more preferably:! ⁇ 60 weight. /. It is.
- tetracaine preferably, brocaine, jib forcein, lidocaine, benzocaine, xylocaine, and their pharmaceuticals are used.
- Compounds selected from the group consisting of chemically acceptable salts include, but are not limited to, these. These may be used alone or in combination of two or more.
- the content of the local anesthetic in the drug-containing base is preferably from 0.1 to 50% by weight, more preferably from 2 to 20% by weight, based on the total amount of the drug-containing base.
- non-steroid anti-inflammatory analgesic used in the present invention preferably, indomethacin, ketoprofen, piroxicam, felbinac, bufoxamac, subbufen, f / renolebiprofen, diclofenac, ibubrofen, and pharmaceutical agents thereof Compounds selected from the group consisting of salts that are acceptable, but are not limited thereto. These may be used alone or in combination of two or more.
- the content of the non-steroid anti-inflammatory analgesic in the drug-containing base is preferably 0.05 to 10% by weight, more preferably 0.2 to 5% by weight, based on the total amount of the drug-containing base. It is. If the content of non-steroid anti-inflammatory analgesic is less than the above range, the effect is insufficient, which is not preferable. If it exceeds the above range, the effect is the same but side effects may be undesirably exhibited:
- the adhesive gel base used in the present invention arbitrarily contains, in addition to the essential components, a water-soluble polymer, a cross-linking agent, water, and a water retention agent, various compounding components used in a normal adhesive gel base. Can be done.
- optional components include, for example, dissolving agents such as N-methyl-12-pyrrolidone, crotamiton, N, N-dimethylacetamide, benzyl alcohol, potato oil, and isopropyl myristate.
- Fatty acids such as stearic acid and oleic acid
- nonionic surfactants such as polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyglycerin fatty acid ester, anionic surfactant, cationic surfactant, and amphoteric surfactant
- Various fields such as "Activity”
- analgesic In addition to the above local anesthetics and non-steroid anti-inflammatory analgesics, a combination of analgesic, antipruritic, astringent, and anti-inflammatory agents such as satyryl acid and its derivatives, camphor, pepper extract, and 1-menthol are used as medicinal ingredients. Can also.
- the drug-containing base of the present invention is obtained by mixing a local anesthetic and a non-steroid anti-inflammatory analgesic as the active ingredients to the above-mentioned adhesive gel base.
- the method for preparing the drug-containing base is not particularly limited. An appropriate amount of a local anesthetic or non-steroid anti-inflammatory analgesic can be blended and kneaded so as to be uniform. The order of mixing is not particularly limited. The active ingredient and the like can also be blended after being dissolved in an appropriate solvent in advance.
- the external patch of the present invention can be obtained by spreading and coating the drug-containing base prepared by the above-mentioned method on a suitable support to form a drug holding layer.
- the coating amount of the drug-containing bases usually, 2 0 0 ⁇ 2 0 0 0 g / m preferably from 5 0 0 ⁇ 1 5 0 0 gZm 2.
- lidocaine was dissolved in propylene glycol, and diclofenac sodium was dissolved in N-methyl-2-pyrrolidone: These lysates were then combined with the other reagents shown in Table 1. The mixture was kneaded until uniform, to obtain a drug-containing base. The drug-containing base obtained in this manner was spread on a nonwoven fabric at 1000 g Zm 2 , a polypropylene liner was attached, and cut into 10 X 14 cm 2. Thus, an external patch was obtained.
- Example 2 A drug-containing base having the formulation shown in Table 2 below was prepared. Specifically, Funirubinaku is dissolved in Kurotami tons, benzocaine and c were dissolved in propylene glycol, kneaded until uniform and other reagents shown in these lysates and Table 2, drug-containing group Agent was obtained. The drug-containing base thus obtained was spread on a non-woven fabric at 100 Og / m 2 , a polypropylene liner was attached, and cut into 10 X 14 cm 2. An external patch was obtained.
- Example 3 A drug-containing base having the formulation shown in Table 3 below was prepared-specifically, indometha was dissolved in crotamiton, and dibuforce hydrochloride was purified water at 10% by weight. / 0 . Next, these dissolved materials and other reagents shown in Table 3 were kneaded until uniform, to obtain a drug-containing base. In this manner the drug-containing base thus obtained was spread at 1 00 O gZm on nonwoven polypropylene liner impregnated, 1 0 X 1 4 was cut so that the cm 2 external patch I got Table 3 Ingredients Blended amount Indomethacin 0.6 Dibucaine hydrochloride 6
- a mouth d + T 100 Example 4
- a drug-containing base having the formulation shown in Table 4 below was prepared. Specifically, ketoprofen is dissolved in crotamiton, and tetracaine hydrochloride is 15% by weight of purified water. / 0 to c then dissolved, kneaded until uniform and other reagents shown in these lysates and Table 4, to obtain a drug-containing base.
- the drug-containing base obtained in this manner is spread on a non-woven fabric at 100 OgZm, a polypropylene liner is attached thereto, and cut into 10 X 14 cm 2 for external use. Patches were obtained: Table 4 Ingredients Compounding amount Ketoprofen 0.5 Tetracaine hydrochloride 8
- a drug-containing base having the formulation shown in Table 6 below was prepared. Specifically, bufuximac is dissolved in N-methyl-2-pyrrolidone, and xylokine is purified water at 10% by weight. / 0 . Next, these lysates and the other reagents shown in Table 6 were kneaded until uniform, to obtain a drug-containing base. As this manner the drug-containing base thus obtained was spread at 1 0 0 0 g Z m 2 on the nonwoven fabric, a polypropylene liner one impregnated, becomes 1 0 X 1 4 cm 2 To give a patch for external use. Table 6 Ingredient content Bufexamac 0.6
- Example 1 Remaining mouth 1 0 0 Comparative Example
- Example 2 An external patch was prepared in the same manner as in Example 1 except that the same amount of purified water was used instead of lidocaine.
- Comparative Example 3 The same amount of purified water as in Example 3 was used instead of indomethacin, and an external patch was produced by the same production method.
- Comparative Example 4 An external patch was prepared in the same manner as in Example 3 except that the same amount of purified water was used instead of dibucaine hydrochloride.
- Test Example The external patches obtained in Examples 1 and 3 and Comparative Examples 1 to 4 were randomly administered to 10 volunteers each having low back pain (that is, applied to the affected area), and a sensory test was performed. The administration time was 12 hours a day, and was performed for 7 days. After the test, volunteers evaluated the effect on a four-point scale: “excellent”, “effective”, “unchanged”, and “deteriorated”. The same test was repeated one week after drug withdrawal, and the test was performed until all patches had been evaluated. Table 7 shows the results. Table 7
- the improvement rates (effective or more) of the patches of Examples 1 and 3 and Comparative Examples 1 to 4 after one week were 90% (9/10) and 100% ( 1 0 Z 10), 20% (2/10), 80% (8 Z 10), 30% (3 Z 10), 70% (7/10), and The rate at which the improvement rate became significant was 70% (7/10), 50% (5Z10), 0% (0, 10), and 30% (3/10), respectively. , 0% (0/10) and 0% (0/10).
- the topical patch consisting of a local anesthetic and a non-steroid anti-inflammatory analgesic (Examples 1 and 3) consisted of a local anesthetic or a non-steroid anti-inflammatory analgesic alone. It shows that it is superior to the external patch (Comparative Examples 1-4). That is, the effectiveness of the external patch of the present invention, which contains both a local anesthetic and a non-steroid anti-inflammatory drug, was confirmed.
- a water-soluble polymer substance, a cross-linking agent, water, and a water-retaining agent are used as essential components in an adhesive gel base, Do-type anti-inflammatory
- An external patch consisting of a drug-containing layer containing a pain applied on a support is extremely effective in relieving pain associated with inflammation such as chronic joint rheumatism, osteoarthritis, and low back pain. ing.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00970054A EP1170020A4 (en) | 1999-12-27 | 2000-10-25 | EXTERNAL USE PADS |
US09/914,265 US7018647B1 (en) | 1999-12-27 | 2000-10-25 | Patches for external use |
JP2001548147A JP4774179B2 (ja) | 1999-12-27 | 2000-10-25 | 外用貼付剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/368718 | 1999-12-27 | ||
JP36871899 | 1999-12-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001047559A1 true WO2001047559A1 (fr) | 2001-07-05 |
WO2001047559A9 WO2001047559A9 (fr) | 2001-11-22 |
Family
ID=18492565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/007451 WO2001047559A1 (fr) | 1999-12-27 | 2000-10-25 | Pastilles a usage externe |
Country Status (4)
Country | Link |
---|---|
US (1) | US7018647B1 (ja) |
EP (1) | EP1170020A4 (ja) |
JP (1) | JP4774179B2 (ja) |
WO (1) | WO2001047559A1 (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002128699A (ja) * | 2000-10-26 | 2002-05-09 | Sankyo Co Ltd | 消炎鎮痛外用剤組成物 |
WO2004012724A1 (ja) * | 2002-08-02 | 2004-02-12 | Medrx Co., Ltd. | 浸透拡散性に優れた消炎鎮痛外用剤 |
WO2004110428A1 (ja) * | 2003-06-11 | 2004-12-23 | Teikoku Seiyaku Co., Ltd. | 消炎鎮痛貼付剤 |
JP2005082512A (ja) * | 2003-09-05 | 2005-03-31 | Medorekkusu:Kk | イオン性の薬物の経皮吸収性を高めた外用剤 |
JP2005145932A (ja) * | 2003-11-19 | 2005-06-09 | Medorekkusu:Kk | 消炎鎮痛外用剤 |
JP2005239709A (ja) * | 2004-01-29 | 2005-09-08 | Medorekkusu:Kk | 消炎鎮痛外用剤 |
JP2008241245A (ja) * | 2007-02-27 | 2008-10-09 | Hisamitsu Pharmaceut Co Inc | 関節リウマチの痛みに対する鎮痛効果を有する外用剤の薬効評価方法 |
WO2009154148A1 (ja) | 2008-06-16 | 2009-12-23 | 帝國製薬株式会社 | 消炎鎮痛外用剤 |
US7655687B2 (en) | 2004-01-29 | 2010-02-02 | Medrx Co., Ltd. | Anti-inflammatory analgesic for external use |
JP2010202663A (ja) * | 2001-10-25 | 2010-09-16 | Endo Pharmaceuticals Inc | 非神経障害性疼痛を処置するための方法 |
WO2010114121A1 (ja) * | 2009-04-02 | 2010-10-07 | ダイヤ製薬株式会社 | 水性ゲル基剤および水性ゲル貼付剤 |
JP2011006465A (ja) * | 2010-09-01 | 2011-01-13 | Medorekkusu:Kk | イオン性の薬物の経皮吸収性を高めた外用剤 |
WO2011074566A1 (ja) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | フェルビナク含有経皮吸収製剤 |
WO2011074567A1 (ja) * | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | 塩基性消炎鎮痛剤含有経皮吸収製剤 |
WO2011074565A1 (ja) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | ピロキシカム含有経皮吸収製剤 |
WO2013027840A1 (ja) | 2011-08-25 | 2013-02-28 | ニプロパッチ株式会社 | 含水貼付剤 |
US9731490B2 (en) | 2008-10-02 | 2017-08-15 | Mylan Inc. | Method for making a multilayer adhesive laminate |
JP2020505422A (ja) * | 2017-01-31 | 2020-02-20 | 帝國製薬株式会社 | リドカインおよびジクロフェナクを含む医薬用貼付剤についての投与計画 |
JP2020505416A (ja) * | 2017-01-31 | 2020-02-20 | 帝國製薬株式会社 | リドカインおよびジクロフェナクを含む神経障害性疼痛の治療用の医薬用貼付剤 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1201232E (pt) * | 1999-07-27 | 2007-07-24 | Hisamitsu Pharmaceutical Co | Emplastros papa uso externo. |
US6761900B2 (en) | 2001-03-12 | 2004-07-13 | Teikoku Pharma Usa, Inc. | Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
ITMI20030414A1 (it) * | 2003-03-06 | 2004-09-07 | Biofarm S R L Ora Biofarmitalia S P A | Tampone con strato di gel con attivita' cosmetica o terapeutica. |
WO2006051818A1 (ja) * | 2004-11-10 | 2006-05-18 | Hisamitsu Pharmaceutical Co., Inc. | 外用製剤及び貼付剤 |
WO2009026178A2 (en) * | 2007-08-17 | 2009-02-26 | Arcion Therapeutics, Inc. | High concentration local anesthetic formulations |
CN101896175B (zh) * | 2007-12-12 | 2013-03-13 | 帝国制药株式会社 | 含有环氧洛芬的水性贴剂 |
US8119694B2 (en) | 2008-08-15 | 2012-02-21 | Arcion Therapeutics, Inc. | High concentration local anesthetic formulations |
WO2014159798A1 (en) | 2013-03-13 | 2014-10-02 | Avery Dennison Corporation | Improving adhesive properties |
US9974754B2 (en) * | 2013-12-18 | 2018-05-22 | Maruishi Pharmaceutical Co., Ltd. | Hydrous adhesive patch |
US9370449B2 (en) | 2014-02-26 | 2016-06-21 | Luma Therapeutics, Inc. | Phototherapy dressing for treating psoriasis |
US20190168016A1 (en) | 2016-02-09 | 2019-06-06 | Luma Therapeutics, Inc. | Methods, compositions and apparatuses for treating psoriasis by phototherapy |
EP3639819B1 (en) * | 2017-06-16 | 2021-11-10 | Medrx Co., Ltd. | Anti-inflammatory and analgesic drug for external use |
CN115708816A (zh) * | 2022-10-20 | 2023-02-24 | 重庆医科大学 | 一种盐酸普鲁卡因水凝胶贴膏剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06145053A (ja) * | 1992-11-06 | 1994-05-24 | Maeda Yakuhin Kogyo Kk | 使用性の改善された消炎鎮痛用皮膚外用貼付剤 |
JPH11171768A (ja) * | 1997-10-15 | 1999-06-29 | Taisho Pharmaceut Co Ltd | 消炎鎮痛外用剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933362A (en) * | 1989-06-06 | 1990-06-12 | Jack Loomstein | Sunburn treatment composition |
JP3004769B2 (ja) * | 1990-05-30 | 2000-01-31 | フェリック株式会社 | 温熱治療用構造物 |
US5173302A (en) * | 1990-09-28 | 1992-12-22 | Medtronic, Inc. | Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs |
JP3115625B2 (ja) * | 1991-03-30 | 2000-12-11 | 帝國製薬株式会社 | リドカイン含有外用貼付剤 |
DE4223004A1 (de) * | 1992-07-13 | 1994-01-20 | Liedtke Pharmed Gmbh | Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie |
JP3526887B2 (ja) * | 1993-04-23 | 2004-05-17 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
EP0698393B1 (en) * | 1993-05-19 | 2002-07-03 | Hisamitsu Pharmaceutical Co., Inc. | 3-l-MENTHOXY-PROPANE-1, 2-DIOL AS SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME |
JPH07223942A (ja) * | 1994-02-03 | 1995-08-22 | Ildong Pharm Co Ltd | プロピオン酸系非ステロイド性薬物を有効成分として含有する新規消炎鎮痛外用ゲル製剤 |
EP1021204B1 (en) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US6455066B1 (en) * | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
-
2000
- 2000-10-25 EP EP00970054A patent/EP1170020A4/en not_active Withdrawn
- 2000-10-25 US US09/914,265 patent/US7018647B1/en not_active Expired - Lifetime
- 2000-10-25 WO PCT/JP2000/007451 patent/WO2001047559A1/ja active Application Filing
- 2000-10-25 JP JP2001548147A patent/JP4774179B2/ja not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06145053A (ja) * | 1992-11-06 | 1994-05-24 | Maeda Yakuhin Kogyo Kk | 使用性の改善された消炎鎮痛用皮膚外用貼付剤 |
JPH11171768A (ja) * | 1997-10-15 | 1999-06-29 | Taisho Pharmaceut Co Ltd | 消炎鎮痛外用剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1170020A4 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4684404B2 (ja) * | 2000-10-26 | 2011-05-18 | 第一三共株式会社 | 消炎鎮痛外用剤組成物 |
JP2002128699A (ja) * | 2000-10-26 | 2002-05-09 | Sankyo Co Ltd | 消炎鎮痛外用剤組成物 |
JP2010202663A (ja) * | 2001-10-25 | 2010-09-16 | Endo Pharmaceuticals Inc | 非神経障害性疼痛を処置するための方法 |
WO2004012724A1 (ja) * | 2002-08-02 | 2004-02-12 | Medrx Co., Ltd. | 浸透拡散性に優れた消炎鎮痛外用剤 |
WO2004110428A1 (ja) * | 2003-06-11 | 2004-12-23 | Teikoku Seiyaku Co., Ltd. | 消炎鎮痛貼付剤 |
JP2005082512A (ja) * | 2003-09-05 | 2005-03-31 | Medorekkusu:Kk | イオン性の薬物の経皮吸収性を高めた外用剤 |
JP2005145932A (ja) * | 2003-11-19 | 2005-06-09 | Medorekkusu:Kk | 消炎鎮痛外用剤 |
JP2005239709A (ja) * | 2004-01-29 | 2005-09-08 | Medorekkusu:Kk | 消炎鎮痛外用剤 |
US7655687B2 (en) | 2004-01-29 | 2010-02-02 | Medrx Co., Ltd. | Anti-inflammatory analgesic for external use |
JP2008241245A (ja) * | 2007-02-27 | 2008-10-09 | Hisamitsu Pharmaceut Co Inc | 関節リウマチの痛みに対する鎮痛効果を有する外用剤の薬効評価方法 |
WO2009154148A1 (ja) | 2008-06-16 | 2009-12-23 | 帝國製薬株式会社 | 消炎鎮痛外用剤 |
JP2009298741A (ja) * | 2008-06-16 | 2009-12-24 | Teikoku Seiyaku Co Ltd | 消炎鎮痛外用剤 |
US10272656B2 (en) | 2008-10-02 | 2019-04-30 | Mylan Inc. | Method for making a multilayer adhesive laminate |
US9731490B2 (en) | 2008-10-02 | 2017-08-15 | Mylan Inc. | Method for making a multilayer adhesive laminate |
WO2010114121A1 (ja) * | 2009-04-02 | 2010-10-07 | ダイヤ製薬株式会社 | 水性ゲル基剤および水性ゲル貼付剤 |
WO2011074566A1 (ja) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | フェルビナク含有経皮吸収製剤 |
WO2011074565A1 (ja) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | ピロキシカム含有経皮吸収製剤 |
JP2011126793A (ja) * | 2009-12-15 | 2011-06-30 | Teikoku Seiyaku Co Ltd | フェルビナク含有経皮吸収製剤 |
WO2011074567A1 (ja) * | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | 塩基性消炎鎮痛剤含有経皮吸収製剤 |
JPWO2011074567A1 (ja) * | 2009-12-15 | 2013-04-25 | 帝國製薬株式会社 | 塩基性消炎鎮痛剤含有経皮吸収製剤 |
JP5677680B2 (ja) * | 2009-12-15 | 2015-02-25 | 帝國製薬株式会社 | 塩基性消炎鎮痛剤含有経皮吸収製剤 |
JP2011006465A (ja) * | 2010-09-01 | 2011-01-13 | Medorekkusu:Kk | イオン性の薬物の経皮吸収性を高めた外用剤 |
WO2013027840A1 (ja) | 2011-08-25 | 2013-02-28 | ニプロパッチ株式会社 | 含水貼付剤 |
JP2020505422A (ja) * | 2017-01-31 | 2020-02-20 | 帝國製薬株式会社 | リドカインおよびジクロフェナクを含む医薬用貼付剤についての投与計画 |
JP2020505416A (ja) * | 2017-01-31 | 2020-02-20 | 帝國製薬株式会社 | リドカインおよびジクロフェナクを含む神経障害性疼痛の治療用の医薬用貼付剤 |
Also Published As
Publication number | Publication date |
---|---|
JP4774179B2 (ja) | 2011-09-14 |
EP1170020A1 (en) | 2002-01-09 |
WO2001047559A9 (fr) | 2001-11-22 |
US7018647B1 (en) | 2006-03-28 |
EP1170020A4 (en) | 2009-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001047559A1 (fr) | Pastilles a usage externe | |
CA2045290C (en) | Plaster with a high content of softening ingredients | |
JP3526887B2 (ja) | 消炎鎮痛外用貼付剤 | |
CA2796575C (en) | Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use | |
GB2273044A (en) | Medicinal patches for percutaneous administration | |
JPH04305523A (ja) | リドカイン含有外用貼付剤 | |
WO2004047820A1 (ja) | 温感パップ剤 | |
EP2305307A1 (en) | Analgesic anti-inflammatory preparation for external application | |
JP2569396B2 (ja) | 経皮投与型薬物用貼付剤 | |
JP3159688B2 (ja) | 経皮吸収テープ剤 | |
WO2004110428A1 (ja) | 消炎鎮痛貼付剤 | |
EP1158967B1 (en) | Transdermal device comprising non-steroidal anti-inflammatory drugs incorporated in acrylic adhesive polymer matrix | |
JPS61275212A (ja) | ケトプロフエン含有パツプ剤 | |
JPH09315964A (ja) | 肩こり・五十肩治療用貼付剤 | |
JP2004083462A (ja) | 外用貼付剤及び外用貼付剤中の薬物のエステル化抑制方法 | |
JP2001302501A (ja) | 肩こり・膝関節痛・五十肩等の治療用貼付剤 | |
JPH09143061A (ja) | 鎮痛剤用経皮吸収製剤 | |
JP2001302503A (ja) | 貼付剤 | |
JP2003183156A (ja) | 外用貼付剤 | |
JPH10316590A (ja) | 局所麻酔用外用剤 | |
JP2001039864A (ja) | フェルビナク含有貼付剤 | |
JP2887549B2 (ja) | 使用性の改善された消炎鎮痛用皮膚外用貼付剤 | |
JPH0656660A (ja) | ジクロフェナクナトリウム含有貼付剤 | |
US20050220851A1 (en) | Matrix type patch containing bronchodilators | |
JPH06135828A (ja) | 経皮吸収性製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): DE ES FR IT NL |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 548147 Kind code of ref document: A Format of ref document f/p: F |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000970054 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09914265 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): BR CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): DE ES FR IT NL |
|
COP | Corrected version of pamphlet |
Free format text: AMENDED CLAIMS AND STATEMENT, ADDED (2 PAGES) |
|
WWP | Wipo information: published in national office |
Ref document number: 2000970054 Country of ref document: EP |